Relay Therapeutics (RLAY) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

RLAY Relay Therapeutics

Watchlist

4.620
+0.050+1.09%

Close Jan 7 16:00 ET

773.31MMarket Cap-1.77P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire16:05 ET
Insider Sale: See Remarks of $RLAY (RLAY) Sells 16,576 Shares
Quiver QuantitativeJan 6 20:45 ET
Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now?
Yahoo FinanceDec 30, 2024 14:57 ET
We Think Relay Therapeutics (NASDAQ:RLAY) Needs To Drive Business Growth Carefully
Simply Wall StDec 19, 2024 10:58 ET
Relay Therapeutics Insider Sold Shares Worth $500,000, According to a Recent SEC Filing
MT NewswiresDec 18, 2024 16:58 ET
Express News | JMP Securities Reiterates Market Outperform on Relay Therapeutics, Maintains $21 Price Target
BenzingaDec 12, 2024 09:28 ET

Comments

Jaguar8

Dec 11, 2024 05:03

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Relay Therapeutics (RLAY) announced updated interim data for RLY-2608, showing an 11.4-month median progression-free survival in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at the recommended Phase 2 dose. The study demonstrated a 39% confirmed objective response rate ...

Trytosaveabit

Dec 11, 2024 05:01

Update

$Relay Therapeutics (RLAY.US)$ Reuters· just
Relay Therapeutics Announces Updated Interim Data for Rly-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival

Jaguar8

Dec 9, 2024 15:07

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Relay Therapeutics (RLAY) announced it will present updated clinical data for RLY-2608 in combination with fulvestrant for treating PI3Kα-mutated, HR+, HER2- locally advanced or metastatic breast cancer at the San Antonio Breast Cancer Symposium (December 10-13, 2024). The presentation, titled 'Efficacy of RLY-2608, a mutant-se...

Jaguar8

Dec 3, 2024 16:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...

Jaguar8

Dec 3, 2024 07:21

NEWS

$Relay Therapeutics (RLAY.US)$
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay Therapeutics (RLAY) and Elevar Therapeutics have announced an exclusive global licensing agreement for lirafugratinib, a potential best-in-class FGFR2 inhibitor for treating FGFR2-driven cholangiocarcinoma and other solid tumors. Under the agreement, Elevar receives worldwide development and c...

Heat List

Overall

No Data